Rachel Abbott was named chief scientific officer of Pan Cancer T, a biotech spin-off from Erasmus MC focused on the discovery and development of next-generation TCR-T therapies against solid tumors.
To access this subscriber-only content please log in or subscribe.
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe